|
Federal Interagency Working Group on Measuring Sexual Orientation and Gender Identity (SOGI)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, CMS, SAMHSA
|
NICHD
|
This working group explores measurement of sexual orientation and gender identity (SOGI), considering multiple different dimensions of sex, gender, and sexuality. The Working Group examines variability in measurement by age, race, ethnicity, and cultural group. It prepares recommendations to the Office of Management and Budget (OMB) and other Federal agencies for the development, testing, and usage of SOGI measures to more accurately describe LGBT populations.
|
|
Federal Partners in Bullying Prevention, Intervention, and Recovery
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, HRSA, IHS, SAMHSA
|
NIMH, NIAAA, NICHD, NIDA
|
This workgroup meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning how to prevent or stop bullying in schools and communities.
|
|
Federal RePORTER
|
Resource Development
|
ACF, ACL, AHRQ, CDC, FDA
|
OD/OER
|
Federal RePORTER is a searchable public database of scientific awards from federal agencies, which allows for portfolio analysis and metrics development across scientific domains. The trans-federal agency consortium called STAR METRICS (Science and Technology for America’s Reinvestment Measuring the Effects of Research on Innovation, Competitiveness, and Science) designed, created, and maintains Federal RePORTER.
|
|
Federal Sudden Unexpected Infant Death/Sudden Infant Death Syndrome (SUID/SIDS) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, FDA, HRSA, IHS, OS
|
NICHD
|
The Federal SUID/SIDS Workgroup represents multiple federal agencies that have established a partnership to coordinate activities, research, and outreach related to reducing infant mortality caused by SUID and SIDS.
|
|
Federal Supply and Demand of Isotopes
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIBIB, NCI
|
This workgroup was formed as a follow-up to the Inaugural Workshop on Isotope Federal Supply and Demand, a workshop now held annually. The workgroup consists of representatives of Federal agencies with the aim of providing a forum for interaction between agencies and departments to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. The US Department of Energy (DOE) is charged with the production of isotopes that are not commercially available and coordinates the informational and production efforts. Dr. Bruce Tromberg, Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is the National Institutes of Health (NIH) point of contact on this topic. The workgroup holds an annual workshop that includes all Federal agencies that use isotopes; the workshop promotes discussion on the use, supply and demand of isotopes in various areas including homeland defense, medicine, agriculture, and basic and applied research. The most recent workshop was held in November 2018. As the representative NIBIB staff work with the NIH Isotope Committee and submit an annual report of NIH’s isotope needs to DOE.
|
|
Federal Tuberculosis (TB) Task Force
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS
|
NICHD, NIAID
|
The Federal Tuberculosis (TB) Task Force is a coalition composed of the federal agencies involved in U.S. TB research and control efforts. Established in 1991, it facilitates coordination of activities among these federal agencies.
|
|
Federal Working Group on Bone Diseases
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA
|
NIAMS, CSR, NCCIH, NCI, NEI, NIA, NIAAA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ODS, OD/DPCPSI/ORWH
|
An interagency committee focusing on osteoporosis and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency''s mission.
|
|
Federal Working Group on Dietary Supplements (FWGoDS)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, CDC, FDA, HRSA, IHS
|
OD/DPCPSI/ODS, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH
|
The Office of Dietary Supplements (ODS) leads the Federal Working Group on Dietary Supplements (FWGoDS) which is comprised of individuals from federal agencies that share information and discuss issues, initiatives, and research related to dietary supplements. The FWGoDS facilitates communication and collaboration between NIH and its federal partners in several ways: co-funding research investigations within NIH, expanding opportunities for research-investigator training, and strengthening collaborative efforts involving dietary supplement research, education, and communication. The FWGoDS meets twice a year and serves as a means of communication between ODS and its federal partners.
|
|
FedTel: Cross-Federal work group on telehealth
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIBIB, NLM, OD/DPCPSI/OBSSR
|
The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. Current topics of emphasis include Telehealth and Health Information Technology (HIT); Technology, Innovation and Standards; Public Education of Telehealth; and Access to Health Care.
|
|
Filovirus Animal Non-Clinical Group (FANG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories.
|